{"id":"W3196278183","doi":"10.1007/s10549-021-06334-0","title":"Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Tolerability; Letrozole; Internal medicine; Breast cancer; Adverse effect; Neutropenia; Metastatic breast cancer; Population; Oncology; Progression-free survival; Hazard ratio; Cancer; Confidence interval; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003107692,0.0002980686,0.000691867,0.0001688447,0.0002197865,0.00002506403,0.0001212111,0.00007132734,0.0001533081],"category_scores_gemma":[0.00003344581,0.0002090546,0.00009190722,0.0005424895,0.0001286293,0.0002613756,0.00005074725,0.0001622476,4.125823e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009750114,"about_ca_system_score_gemma":0.000341719,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.04696929,"about_ca_topic_score_gemma":0.03836628,"domain_scores_codex":[0.9973242,0.0001875398,0.0006755182,0.0006151013,0.0006902756,0.0005074244],"domain_scores_gemma":[0.9979581,0.0003038429,0.0002869089,0.0005876287,0.0006449293,0.0002185461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1967481,0.01615704,0.1920351,0.00007896033,0.0007385663,0.00003474682,0.006042198,0.0009871738,0.01464105,0.00004556293,0.00001584264,0.5724757],"study_design_scores_gemma":[0.1973764,0.0131014,0.7741233,0.000647157,0.0001659273,0.00006330045,0.00688328,0.001584191,0.005090368,0.0004678535,0.000222849,0.0002740625],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834991,0.003819286,0.00003956477,0.001982508,0.00008175538,0.003234532,0.0073152,0.00002228524,0.000005766582],"genre_scores_gemma":[0.9948252,0.001555249,0.0001700734,0.00004927531,0.0002722048,0.001473656,0.001543611,0.00004628648,0.00006445213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5820882,"threshold_uncertainty_score":0.9791811,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1592860876520025,"score_gpt":0.4842063134928922,"score_spread":0.3249202258408896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}